68Ga-Pentixafor PET/CT 成像华氏巨球蛋白血症/淋巴浆细胞淋巴瘤的趋化因子受体4表达并与18F-FDG PET/CT比较
68Ga-pentixafor PET/CT阳性率显著高于18F-FDG PET/CT(100% vs. 58.8%;P = 0.023),在淋巴结受累检测中阳性率也显著更高(76.5% vs. 11.8%;P = 0.003),提示其可能是评估WM/LPL有前景的显像剂。
要点
- 68Ga-pentixafor PET/CT在WM/LPL患者中阳性率100%,高于18F-FDG的58.8%(P = 0.023)。
- 淋巴结受累检测阳性率68Ga-pentixafor显著高于18F-FDG(76.5% vs. 11.8%;P = 0.003)。
- 骨髓受累灵敏度68Ga-pentixafor为94.1%、18F-FDG为58.8%(P = 0.077)。
核心结论
- 68Ga-pentixafor可能是评估WM/LPL有前景的显像剂。
研究设计与样本
- PET/CT阳性定义为存在局灶性阳性病变或弥漫性骨髓模式(摄取高于肝脏)。
主要发现
- 68Ga-pentixafor PET/CT总体阳性率高于18F-FDG PET/CT(100% vs. 58.8%;P = 0.023)。
- 骨髓受累检测灵敏度68Ga-pentixafor为94.1%、18F-FDG为58.8%(P = 0.077)。
- 淋巴结受累检测阳性率68Ga-pentixafor显著高于18F-FDG(76.5% vs. 11.8%;P = 0.003)。
- 68Ga-pentixafor较18F-FDG检出更多椎旁和中枢神经系统受累。
关键数值与推荐
- 阳性PET/CT判定标准为存在局灶性阳性病变或弥漫性骨髓模式且摄取高于肝脏。
临床怎么用
- 对WM/LPL患者,68Ga-pentixafor PET/CT在总体阳性率、淋巴结及椎旁/中枢神经系统受累检出方面优于18F-FDG PET/CT。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
18F-FDG PET/CT has some limitations in the evaluation of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL), an indolent B-cell lymphoma that primarily involves the bone marrow. Because there is a high level of chemokine receptor 4 expression in the B cells of WM/LPL patients, we performed a prospective cohort study to evaluate the performance of 68Ga-pentixafor, which targets chemokine receptor 4 in WM/LPL, and to compare it with the performance of 18F-FDG. Methods: Seventeen patients with WM/LPL were recruited. All patients underwent both 68Ga-pentixafor PET/CT and 18F-FDG PET/CT. A positive PET/CT result was defined as the presence of focal lesions with positive PET results or diffuse bone marrow patterns (uptake > liver). The rates of positive results for PET/CT scans of bone marrow, lymph nodes, and other extramedullary involvement were statistically compared. Results:68Ga-pentixafor PET/CT had a higher rate of positive results than 18F-FDG PET/CT (100% vs. 58.8%; P = 0.023) in the recruited WM/LPL patients. The sensitivities of 68Ga-pentixafor PET/CT and 18F-FDG PET/CT for detecting bone marrow involvement were 94.1% and 58.8%, respectively (P = 0.077). In terms of detecting lymph node involvement, 68Ga-pentixafor PET/CT had a significantly higher rate of positive results than 18F-FDG PET/CT (76.5% vs. 11.8%; P = 0.003). In addition, 68Ga-pentixafor detected more paramedullary and central nervous system involvement than 18F-FDG. Conclusion:68Ga-pentixafor might be a promising imaging agent for the assessment of WM/LPL.
引用
- Luo Y, Cao X, Pan Q, et al. 68Ga-Pentixafor PET/CT for Imaging of Chemokine Receptor 4 Expression in Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to 18F-FDG PET/CT. J Nucl Med. 2019. PMID: 31101745. doi:10.2967/jnumed.119.226134
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。